Clinical Trial Update: Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/2 study evaluating adverse events and efficacy of Telisotuzumab Adizutecan in combination with a PD-1 inhibitor for a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1 immune checkpoint inhibitor (PD-1 inhibitor)
• Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Snippet

Sponsor: AbbVie | Conditions: Non Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: RECRUITING